Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED BALANCE SHEETS

v3.19.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Jun. 30, 2018
Dec. 31, 2017
Current assets    
Cash $ 3,878 $ 142
Prepaid Expenses 23,323 3,006
Total current assets 27,201 3,148
Total Assets 27,201 3,148
Current liabilities    
Accounts payable 154,709 270,851
Accrued expenses 515,714 493,164
Accrued interest payable 463,703 382,302
Related party payables 1,219,803 1,026,819
Stock subscriptions payable 557
Notes payable - current - related parties [1] 678,691 630,575
Notes payable - current - non related parties 164,073 [2] 163,574
Total current liabilities 3,197,250 2,967,285
Total Liabilities 3,197,250 2,967,285
Stockholders' Deficit    
Preferred stock, value
Common stock, $0.00001 par value; 800,000,000 shares authorized; 116,751,078 and 109,409,930 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively 1,172 1,096
Additional paid-in capital 14,874,547 14,785,051
Accumulated deficit (17,997,030) (17,703,171)
Total Transbiotec, Inc. stockholders' deficit (3,121,297) (2,917,010)
Noncontrolling interest (48,752) (47,127)
Total Stockholders' Deficit (3,170,049) (2,964,137)
Total Liabilities and Stockholders' Deficit 27,201 3,148
Series A Preferred Stock [Member]    
Stockholders' Deficit    
Preferred stock, value $ 14 $ 14
[1] Includes unamortized debt issuance costs related to detached warrants of $27,153 and $19,969 at June 30, 2018 and December 31, 2017, respectively
[2] Includes unamortized beneficial conversion features related to convertible notes of $5,501 and none at June 30, 2018 and December 31, 2017, respectively